Profile data is unavailable for this security.
About the company
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
- Revenue in USD (TTM)399.36m
- Net income in USD-151.58m
- Incorporated2002
- Employees517.00
- LocationAmicus Therapeutics Inc3675 Market StreetPHILADELPHIA 19104United StatesUSA
- Phone+1 (215) 921-7600
- Fax+1 (609) 662-2001
- Websitehttps://www.amicusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Summit Therapeutics Inc | 0.00 | -614.93m | 2.72bn | 105.00 | -- | 35.49 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Arcellx Inc | 110.32m | -70.69m | 2.72bn | 130.00 | -- | 5.39 | -- | 24.16 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.76bn | 91.00 | -- | 6.40 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 726.44m | -61.29m | 2.82bn | 597.00 | -- | 6.37 | -- | 3.79 | -0.3774 | -0.3774 | 4.43 | 2.62 | 1.09 | 1.96 | 9.05 | 1,216,812.00 | -9.17 | -27.50 | -12.81 | -32.73 | 94.27 | 95.62 | -8.44 | -38.35 | 2.28 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 2.87bn | 525.00 | -- | 15.16 | -- | 15.42 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| CG Oncology Inc | 204.00k | -67.80m | 2.89bn | 61.00 | -- | -- | -- | 13,128.00 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Janux Therapeutics Inc | 8.08m | -58.29m | 2.90bn | 64.00 | -- | 7.66 | -- | 364.30 | -1.34 | -1.34 | 0.1837 | 7.44 | 0.0217 | -- | -- | 126,296.90 | -15.66 | -- | -16.31 | -- | -- | -- | -721.18 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 2.90bn | 497.00 | -- | 7.96 | -- | 11.84 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Azenta Inc | 641.02m | -17.37m | 2.97bn | 3.50k | -- | 1.20 | 41.85 | 4.56 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.04bn | 517.00 | -- | 18.31 | -- | 7.41 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Ideaya Biosciences Inc | 23.38m | -112.96m | 3.04bn | 124.00 | -- | 4.26 | -- | 129.97 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.22bn | 251.00 | -- | 3.30 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.36bn | 18.00k | -- | 1.87 | 35.16 | 1.05 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.36bn | 557.00 | -- | 5.16 | -- | 2,767.23 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
Data as of Apr 30 2024. Currency figures normalised to Amicus Therapeutics Inc's reporting currency: US Dollar USD
61.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Dec 2023 | 28.06m | 9.50% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 27.72m | 9.38% |
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 27.40m | 9.28% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 20.65m | 6.99% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 15.19m | 5.14% |
| Redmile Group LLCas of 31 Dec 2023 | 14.83m | 5.02% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 13.16m | 4.46% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 12.43m | 4.21% |
| William Blair Investment Management LLCas of 31 Dec 2023 | 11.69m | 3.96% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 11.67m | 3.95% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
